- Home
- WSBC vs RCUS Comparison
WSBC vs RCUS Comparison
Compare WSBC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSBC | RCUS |
|---|---|---|
| Founded | 1870 | 2015 |
| Country | United States | United States |
| Employees | 2969 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WSBC | RCUS |
|---|---|---|
| Price | $40.61 | $28.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $39.25 | $31.90 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $7.06 | $45.62 |
| P/E Ratio | $16.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.18 | $8.84 |
| 52 Week High | $41.27 | $31.74 |
Technical Indicators
Market Signals| Indicator | WSBC | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 67.08 | 53.36 |
| Support Level | $33.05 | $19.78 |
| Resistance Level | N/A | $28.72 |
| Average True Range (ATR) | 0.86 | 1.42 |
| MACD | 0.05 | -0.41 |
| Stochastic Oscillator | 78.74 | 45.17 |
Price Performance
Historical ComparisonAbout WSBC WesBanco Inc.
Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.